Table 2.
Analysis of Overall Survival Defined From the Date of Original Diagnosis of Colorectal Cancer
| KRAS Statusa | No. of Patients |
Median OS (95% CI), mo |
3-Year Survival Estimate (95% CI) |
5-Year Survival Estimate (95% CI) |
Pb |
|---|---|---|---|---|---|
| Synchronous group | |||||
| WT | 39 | 36.3 (21.8–58.3) | 0.51 (0.33–0.66) | 0.28 (0.12–0.46) | .55 |
| Mutant | 25 | 40.3 (27.3–51.0) | 0.59 (0.36–0.77) | 0.16 (0.03–0.38) | |
| Metachronous group | |||||
| WT | 31 | 68.4 (53.5–95.1) | 0.83 (0.64–0.93) | 0.65 (0.44–0.79) | .37 |
| Mutant | 15 | 92.0 (51.8 to NA) | 0.93 (0.61–0.99) | 0.69 (0.37–0.87) |
Abbreviations: CI, confidence interval; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NA, not applicable; OS, overall survival; WT, wild type.
a
Patients in the synchronous group had metastatic disease at the time of diagnosis; patients in the metachronous group developed metastases after their initial diagnosis of localized disease.
b
P values for OS were calculated with the log-rank test.